Particle.news

White House Withdraws Heidi Overton's FDA Nomination

Senior officials said she lacked Senate support, leaving the FDA without a Senate‑confirmed commissioner.

Overview

  • A White House official confirmed late Tuesday that the administration pulled Dr. Heidi Overton’s nomination just before the Senate HELP Committee was to vote, saying she did not have enough votes to move forward.
  • The withdrawal follows weeks of bipartisan pressure over Overton’s record on childhood vaccine policy, the FDA’s authorization of fruit‑flavored vapes, and her comments about the abortion pill mifepristone.
  • Senate HELP Committee chair Bill Cassidy publicly disputed the White House account and said the nomination was dropped after some pro‑life Republicans sought final assurances on abortion‑related policies that the administration would not provide.
  • Acting Commissioner Kyle Diamantas will continue to lead the agency while the White House weighs replacements, with reports naming Sen. Roger Marshall as one possible nominee.
  • The decision deepens a leadership gap at the FDA after Marty Makary’s May resignation and raises questions about who will handle major pending matters such as the agency’s mifepristone safety review due in March 2027.